Doxorubicin-based chemotherapy for diffuse large B-cell lymphoma in elderly patients : Comparison of treatment outcomes between young and elderly patients and the significance of doxorubicin dosage

✍ Scribed by Keun-Wook Lee; Dae-Young Kim; Tak Yun; Dong-Wan Kim; Tae-You Kim; Sung-Soo Yoon; Dae Seog Heo; Yung-Jue Bang; Seonyang Park; Byoung Kook Kim; Noe Kyeong Kim

• Publisher: John Wiley and Sons
• Year: 2003
• Tongue: English
• Weight: 138 KB
• Volume: 98
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/cncr.11846

✦ Synopsis

BACKGROUND.

Although many studies of elderly patients with non-Hodgkin lymphoma have focused on the dose intensity of chemotherapy, few studies have restricted the histologic inclusion criteria such that only patients with diffuse large B-cell lymphoma (DLCL) are considered. In the current study, treatment outcomes for elderly patients (age Ն 60 years) were analyzed, with emphasis on the dose intensity of doxorubicin. Between 1994 and 2000, 195 patients with DLCL were treated initially with doxorubicin-based chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone; or cyclophosphamide, vincristine, bleomycin, doxorubicin, procarbazine, and prednisone). Of these patients, 70 were aged 60 years or older.

METHODS.